Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 39 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Urology

Cognitive fusion targeted biopsy is not inferior to systematic biopsy in metastatic prostate cancer: a single-center, paired study

  • Yonghai Chen1
  • Xingli Shan1
  • Linjun Hu1
  • Sijia Xing1
  • Qingyang Liu1
  • Chengming Xie1
  • Houshan Ning1
  • Hongsong Bai1
  1. 1Department of Urology, Beijing Chaoyang Huanxing Cancer Hospital, Beijng, China
Read full textDOICite

Abstract

Background and purpose: Although cognitive fusion-targeted biopsy (CF-TB) is less invasive than systematic biopsy (SB), evidence regarding its diagnostic efficacy in metastatic prostate cancer (mPCa) remains limited. This study aimed to compare the pathological positive rates of CF-TB and SB in diagnosing mPCa.

Methods: This study included 113 patients with mPCa who underwent transperineal CF-TB 3–4 needles and 12 needles SB under the guidance of MRI /TRUS cognitive fusion in Huanxing Tumor Hospital of Chaoyang District, Beijing, from January 2019 to December 2025. The primary endpoint was the pathological positive rate. The McNemar test was used to compare the two biopsy methods.

Results: The median age was 70 years (IQR: 65-75.5), the median total PSA before biopsy was 21 ng / mL (IQR: 10.5–38.5), and the median prostate volume was 40 mL (IQR: 28–60). Among the 113 patients, 98 (86.7%) had positive digital rectal examination (DRE), and 75 (66.4%) had PI-RADS 5 lesions on mpMRI. The positive rates of CF-TB and SB were 98.2% and 96.5%, respectively. There was no significant difference in the positive detection rate between the two groups (McNemar ‘s Χ2 = 0.6667, P = 0.414), and the consistency was as high as 94.7%. The positive rate difference between the two methods was − 1.77%, and the 95% confidence interval was [-4.5%, 1.0%].

Conclusion: In patients with DRE positive and high PSA and PI-RADS score 5, CF-TB can replace SB and avoid missed diagnosis in this specific high-risk subgroup.

Related

  1. Targeted biopsy plus systematic biopsy versus targeted saturation biopsy plus systematic biopsy for the detection of clinically significant prostate cancer: A comparative study.
    Ashish Varshney, Umesh Sharma, Hemant Goel +1
    Indian journal of urology : IJU : journal of the Urological Society of IndiaPeer-reviewedCC BY-NC-SAFull textGeneral medicineEurope PMC
  2. Prospective Comparison of Cognitive MRI-Targeted Biopsy Under Micro-Ultrasound Guidance Versus MRI/Ultrasound Fusion-Guided Transperineal Biopsy for Clinically Significant Prostate Cancer Detection
    Agostino Fraia, Sara Riolo, Francesco Di Bello +13
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
  3. Targeted biopsy with or without systematic biopsy in PI-RADS-stratified prostate biopsy: a risk-adapted narrative review and clinical proposal
    Ye Wu, Yun Wu, Qiang Lu +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  4. Non-inferior survival and enhanced longevity with initial low-dose versus full-dose enzalutamide: a single-centre real-world prostate cancer study
    O. Gorobets, V. Vinh-Hung
    medRxivPreprintCC BY-NC-NDFull textOncologymedRxiv
  5. Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer
    Varun Nandakumar, Georges Gebrael, Neeraj Agarwal
    The OncologistPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC

Cite

BibTeXRIS
BibTeX
@article{chen2026cognitive,
  title = {{Cognitive fusion targeted biopsy is not inferior to systematic biopsy in metastatic prostate cancer: a single-center, paired study}},
  author = {Yonghai Chen and Xingli Shan and Linjun Hu and Sijia Xing and Qingyang Liu and Chengming Xie and Houshan Ning and Hongsong Bai},
  journal = {BMC Urology},
  year = {2026},
  month = jul,
  doi = {10.1186/s12894-026-02288-x},
  url = {https://doi.org/10.1186/s12894-026-02288-x},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Cognitive fusion targeted biopsy is not inferior to systematic biopsy in metastatic prostate cancer: a single-center, paired study
AU  - Yonghai Chen
AU  - Xingli Shan
AU  - Linjun Hu
AU  - Sijia Xing
AU  - Qingyang Liu
AU  - Chengming Xie
AU  - Houshan Ning
AU  - Hongsong Bai
PY  - 2026
DA  - 2026/07/30
JO  - BMC Urology
DO  - 10.1186/s12894-026-02288-x
UR  - https://doi.org/10.1186/s12894-026-02288-x
AB  - Background and purpose: Although cognitive fusion-targeted biopsy (CF-TB) is less invasive than systematic biopsy (SB), evidence regarding its diagnostic efficacy in metastatic prostate cancer (mPCa) remains limited. This study aimed to compare the pathological positive rates of CF-TB and SB in diagnosing mPCa.  Methods: This study included 113 patients with mPCa who underwent transperineal CF-TB 3–4 needles and 12 needles SB under the guidance of MRI /TRUS cognitive fusion in Huanxing Tumor Hospital of Chaoyang District, Beijing, from January 2019 to December 2025. The primary endpoint was the pathological positive rate. The McNemar test was used to compare the two biopsy methods.  Results: The median age was 70 years (IQR: 65-75.5), the median total PSA before biopsy was 21 ng / mL (IQR: 10.5–38.5), and the median prostate volume was 40 mL (IQR: 28–60). Among the 113 patients, 98 (86.7%) had positive digital rectal examination (DRE), and 75 (66.4%) had PI-RADS 5 lesions on mpMRI. The positive rates of CF-TB and SB were 98.2% and 96.5%, respectively. There was no significant difference in the positive detection rate between the two groups (McNemar ‘s Χ2 = 0.6667, P = 0.414), and the consistency was as high as 94.7%. The positive rate difference between the two methods was − 1.77%, and the 95% confidence interval was [-4.5%, 1.0%].  Conclusion: In patients with DRE positive and high PSA and PI-RADS score 5, CF-TB can replace SB and avoid missed diagnosis in this specific high-risk subgroup.
SN  - 1471-2490
ER  -